Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 415 respiratory deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of respiratory deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Respiratory Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of 415 respiratory deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of respiratory deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse respiratory collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Respiratory Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of respiratory trends and structure of deals entered into by leading biopharma companies worldwide.Respiratory Collaboration and Licensing Deals includes:
- Trends in respiratory dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of respiratory deal records covering pharmaceutical and biotechnology
- The leading respiratory deals by value
- Most active respiratory licensing dealmakers
In Respiratory Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Respiratory Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in respiratory dealmaking
Chapter 3 - Financial deal terms for respiratory partnering
Chapter 4 - Leading respiratory deals and dealmakers
Chapter 5 - Respiratory contract document directory
Chapter 6 - Respiratory dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics
- AazeinTx
- Abbott Laboratories
- Abbvie
- Abingworth Life Sciences
- Abionic
- ABVC BioPharma
- Acceleron Pharma
- Acrobat Genomics
- Actelion
- AdAlta
- Adalvo
- Adamis Pharmaceuticals
- adMare BioInnovations
- ADM Tronics
- Advanz Pharma
- Advent Therapeutics
- Aerami Therapeutics
- Aerogen
- AeroRx Therapeutics
- Aerpio Pharmaceuticals
- AgeX Therapeutics
- Aidoc
- AIT Therapeutics
- Akari Therapeutics
- Akonni Biosystems
- Alex Therapeutics
- Allakos
- Allegheny Technologies
- Allinaire Therapeutic
- Alpine Immune Sciences
- Altavant Sciences
- Altum Pharmaceuticals
- Aluna
- Alveolus
- Alvotech
- American Association for Laboratory Accreditation
- American College of Chest Physicians
- American Lung Association
- Amneal Pharmaceuticals
- AMO Pharma
- Amyndas Pharmaceuticals
- Analytics 4 Life
- AnGes MG
- Anthem
- Anthem Bluecross
- Apple
- Aptar Pharma
- Aptuit
- Arch Biopartners
- Arcturus Therapeutics
- Arena Pharmaceuticals
- Aridis Pharmaceuticals
- Aristea Therapeutics
- Ark Biosciences
- ARS Pharmaceuticals
- ArtiQ
- ARUP Laboratories
- AssisTek
- Asthma UK
- AstraZeneca
- Athersys
- Atrapos Therapeutics
- aTyr Pharma
- Avicenna Technology
- Avrobio
- AzarGen Biotechnologies
- Bausch Health Companies
- Bayer
- Baylor Health Care System
- Beijing Tide Pharmaceutical
- Ben-Gurion University
- BenevolentAI
- Be The Match BioTherapies
- Beth Israel Deaconess Medical Center
- BetterLife Pharma
- Beyond Air
- Bicycle Therapeutics
- Bill and Melinda Gates Foundation
- Bio-Me
- Bio-Techne
- Bioforum
- BioKey
- BioLink Life Sciences
- Biolojic Design
- BioLum Sciences
- Biomedical Advanced Research and Development Authority
- BiomEdit
- BioMed X Innovation Center
- Biophytis
- BiosanaPharma
- BioVersys
- Blanver
- Blu Biotech
- Blue Cross Blue Shield Association
- Blue Shield of California
- BNC Korea
- Boehringer Ingelheim
- Bonne Santé Group
- Boomer Esiason Foundation
- Boston Scientific
- Boston University School of Medicine
- Brainomix
- Breath Therapeutics
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- BrightInsight
- Bristol-Myers Squibb
- British Lung Foundation
- Broncus Technologies
- Brown University
- C4X Discovery
- California Institute for Biomedical Research
- California Institute for Regenerative Medicine
- Cambridge Healthcare Innovations
- Cannex Scientific
- Cantex Pharmaceuticals
- CARB-X
- Cardiff University
- Cardiovascular Systems
- Carnegie Mellon University
- Cedars-Sinai Medical Center
- Celgene
- Cellect Biotechnology
- CELLINK
- Cellix Bio
- Celltrion
- Celularity
- Charak Foundation
- Charite Universitatsmedizin Berlin
- Chiesi Farmaceutici
- Children's Hospital Boston
- China Medical System
- Chronolife
- Cilag AG
- Cincinnati Children’s Hospital Medical Center
- Cipher Pharmaceuticals
- Cipla
- Circassia
- Citius Pharmaceuticals
- Clalit Health Services
- Clario
- CN Bio
- Coalition for Epidemic Preparedness Innovations
- Coeptis Therapeutics
- CohBar
- Collplant
- Combioxin
- Commense
- Commonwealth of Pennsylvania
- Context Therapeutics
- COPD Foundation
- Corsair Pharma
- Cosmo Pharmaceuticals
- CosmosID
- Covalon Technologies
- CRS Bio
- CrystecPharma
- CSL
- CSL Behring
- CS Pharmaceuticals
- Cue Health
- Curadev Pharma
- Curetis
- CureVac
- CVD Equipment
- CytoReason
- Cytovation
- Daewoong Pharmaceutical
- Dalton Pharma Services
- Department of Defense
- Dermira
- Deverra Therapeutics
- DevPro Biopharma
- Diffusion Pharmaceuticals
- Diomics
- Donnelley Financial Solutions
- Duke Clinical Research Institute (DCRI)
- Duke University
- Dymax
- Eagle Pharmaceuticals
- Edesa Biotech
- Eisai
- Empatica
- ENA Respiratory
- Endpoint Health
- Enzyvant Science
- Epistemic AI
- Erasmus University Medical Center
- Essential Pharmaceuticals
- Ethris
- European Union
- Everest Medicines
- EvolveImmune Therapeutics
- Evommune
- Evotec
- Experimental Therapeutics Centre of Singapore
- Fannin
- Faron Pharmaceuticals
- Fibrocor Therapeutics
- FibroGenesis
- Flagship Pioneering
- Florica Therapeutics
- Fluidda
- fluidIQ
- Food and Drug Administration (FDA)
- Forge Therapeutics
- Foundation for Sarcoidosis Research
- Fred Hutchinson Cancer Research Center
- Fujifilm Diosynth Biotechnologies
- FUJIFILM SonoSite
- Fulcrum Therapeutics
- Fusion Genomics
- Galapagos
- Gatehouse Bio
- Geisinger Health System
- GEn1E Lifesciences
- Genentech
- Genomadix
- Genome Institute of Singapore
- GenScript ProBio
- Genten Therapeutics
- German Government
- Getz Healthcare
- Gilead Sciences
- Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals S.A.
- Global Access Diagnostics
- Global Coalition for Adaptive Research
- GlobalLogic
- GoodRx
- Gossamer Bio
- Government of Israel
- GPCR Therapeutics
- Graviton Bioscience
- Green Park Collaborative
- GRI Bio
- Grifols
- GSK
- Guangzhou Institute of Respiratory Disease
- Haisco Pharmaceutical
- Hangzhou Chance Pharmaceuticals
- Haplogen
- Harbour Biomed
- Harvard Stem Cell Institute
- Harvard University
- Harvest Capital Strategies
- HCmed Innovations
- Healios K.K.
- Healium Medical
- Health Care Originals
- HealthPrize Technologies
- HealthSnap
- Hebrew University of Jerusalem
- Hemovent
- Henry M. Jackson Foundation
- Highmark Health
- Hikma Pharmaceuticals
- Honeywell
- Hong Kong Polytechnic University
- Hoth Therapeutics
- Humanetics
- Hyfe
- i2c Pharmaceutical Services
- iBio
- IBM
- Icagen
- Iconovo
- IDbyDNA
- IDT Biologika
- Illumina
- Imbio
- Immune Therapeutics
- Imperial College London
- Inari Medical
- Incyte
- Industrial Technology Research Institute
- Inhalation Sciences
- Inhalon Biopharma
- Inhibrx
- Innovare
- Innovate UK
- Innova Vascular
- Innovus Pharmaceuticals
- Inovio Pharmaceuticals
- Inovytec
- Insmed Inc
- Inspira Technologies
- Instem
- Institut Kanser Negara
- Integrated Computer Solutions
- Intrexon
- Inventiva
- InVixa
- Itamar Medical
- Janssen Pharmaceuticals
- Janssen Research & Development
- Janssen Sciences
- Jiangsu QYuns Therapeutics
- Johannes Gutenberg University
- Johns Hopkins University
- Johnson & Johnson Innovation
- Kaleido Biosciences
- Kamada
- KangWon University Institute of Medical Science
- KARE Biosciences
- Karolinska Institute
- Kashiv BioSciences
- Kennedy Institute of Rheumatology
- Keyence
- Kindeva Drug Delivery
- Knopp Biosciences
- Koye Pharmaceuticals
- Kyorin Pharmaceutical
- La Jolla Institute for Allergy & Immunology
- Lassen Therapeutics
- Launch Therapeutics
- Laurel Venture Capital
- Leading BioSciences
- Lee's Pharmaceutical
- Leidos
- LEO Pharma
- LianBio
- LifeArc
- Ligand Pharmaceuticals
- Light Chain Bioscience
- LightDeck Therapeutics
- Lipigon Pharmaceuticals
- Locus Biosciences
- Lotus Pharmaceuticals
- Lumen Biomedical
- Luminex
- LuminUltra
- Lundquist Institute
- Lung Biotechnology
- Lung Therapeutics
- Lung Transplant Foundation
- Lurie Children's Hospital of Chicago
- Lyomark Pharma
- Lyra Therapeutics
- mAbXience
- Macau University of Science and Technology
- MannKind Biopharmaceuticals
- Marinomed Biotechnologie
- Massachusetts General Hospital
- Matrix Biomed
- Max Biopharma
- Mayo Clinic
- Medical International Research
- Medical Technology Enterprise Consortium
- Medicines Discovery Catapult
- MediciNova
- MedImmune
- MediPines
- Meissa Vaccines
- Melinta Therapeutics
- Melior Pharmaceuticals
- Menarini
- Menarini Asia-Pacific
- Merck and Co
- Mesoblast
- Metaba
- Methapharm
- Microbio Shanghai
- Mitsubishi Tanabe Pharma
- Moderna
- Momenta Pharmaceuticals
- Monopar Therapeutics
- Morphic Therapeutic
- Mount Sinai Health System
- MSD
- Mundipharma
- Mylan Pharmaceuticals
- Myovant Sciences
- Nano-X Imaging
- Nanopharm
- NanoString Technologies
- NantKwest
- Nanyang Technological University
- Nashville Biosciences
- National Healthcare Services (NHS)
- National Health Service
- National Heart
- Lung and Blood Institute
- National Institute for Environmental Health Sciences
- National Institute for Health and Care Research Respiratory Translational Research Collaboration
- National Institute of Allergy and Infectious Diseases
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health
- National Jewish Health
- National Kidney Foundation
- National Organization for Rare Disorders
- National Research Council Canada
- National Science Foundation
- Nepean Blue Mountains Local Health District’s Nepean Hospital
- Nephron Pharmaceuticals
- NeuCen BioMed
- Neurocare Group
- NeuroRx
- Nexel
- NitricGen
- Nitto Denko
- North Carolina State University
- NorthStar Medical Radioisotopes
- Northwestern University
- Novartis
- NoveCite
- Novellus Therapeutics
- NRx Pharmaceuticals
- NTC
- Nuance Pharma
- Numedicus
- NuMedii
- NuvoAir
- ObvioHealth
- Olympus Respiratory America
- Omdana Therapeutics
- One BioMed
- Oneness Biotech
- Onymos
- OpGen
- Organicell Regenerative Medicine
- Orgenesis
- Orion
- Oslo University Hospital
- Owkin
- Owlstone Medical
- Palisade Bio
- Pantherics
- Paragonix Technologies
- Paratek Pharmaceuticals
- PARI Pharma
- Partner Therapeutics
- Patara Pharma
- Patient-Centered Outcomes Research Institute
- Peking University
- Penumbra
- Perrigo
- Pharmbio Korea
- Philips
- Pieris Pharmaceuticals
- Pluristem Therapeutics
- Polarean Imaging
- Polyphor
- Precisio Biotix Therapeutics
- Precision Image Analysis
- Propeller Health
- ProQR Therapeutics
- Protalix BioTherapeutics
- Pulmatrix
- Pulmodyne
- Pulmonary Fibrosis Foundation (PFF)
- Pulmonomy
- PulmoSIM Therapeutics
- Pulmotree Medical
- Pulthera
- Punjab Province
- PureTech Health
- QOL Devices
- Quartesian Clinical Research
- Quebec Government
- Quercis Pharma
- R4D Biotech
- Rabin Medical Center (Beilinson Hospital)
- RapidAI
- ReAlta Life Sciences
- Recipharm
- Recludix Pharma
- Recurrent Respiratory Papillomatosis Foundation
- RedHill Biopharma
- Redox
- Redx Pharma
- Renovion
- Resilient Biotics
- RespirAI Medical
- Respira Therapeutics
- RespiraWorks
- RespireRx Pharmaceuticals
- resTORbio
- Revon Systems
- RION
- Roche
- Roivant Sciences
- Royal Philips Electronics
- RS BioTherapeutics
- Rubedo Life Sciences
- RxCap
- Samumed
- Sandoz
- Sanofi
- Santhera Pharmaceuticals
- SarcoMed USA
- Savana
- Savara Pharma
- Scholar Rock
- Science 37
- Scleroderma Research Foundation
- Seelos Therapeutics
- Sema4
- Sensible Medical Innovations
- SenzaGen
- Seqirus
- Seqster
- Serum Institute of India
- Shandong Luoxin Pharma
- Shanghai Ark Biopharmaceutical
- Shaperon
- Sheba Medical Center
- Shenzhen Institutes of Advanced Technology
- Siemens Healthineers
- Silence Therapeutics
- Simulations Plus
- Siolta Therapeutics
- SiteOne Therapeutics
- Sleepiz
- Sonde Health
- Sonmol
- Sosei Heptares
- SpeeDx
- Spesana
- Spire Health
- SQI Diagnostics
- Stanford University School of Medicine
- Statera Biopharma
- Stemedica Cell Technologies
- Stevanato
- Stimit
- Strados Labs
- Sumitomo Dainippon Pharma
- Sumitovant Biopharma
- Sunnybrook Research Institute
- Sunovion Pharmaceuticals
- SUNY Upstate Medical University
- Sutter Health
- Synergie Lyon Cancer
- Synthonics
- Taiba
- Taiho
- Takeda Pharmaceutical
- TARGET PharmaSolutions
- TB Alliance
- Tektronix Component Solutions
- Telesair
- Tetra Bio-Pharma
- Teva Pharmaceutical Industries
- Texas Lung Injury Institute
- TFF Pharmaceuticals
- The Alfred Hospital
- Therma Bright
- Thermo Fisher Scientific
- Third Pole Therapeutics
- Three Lakes Foundation
- Tivic Health Systems
- TMM Software
- toSense
- Transpire
- Trevena
- TrialSpark
- United Therapeutics
- University of California
- Davis
- University of California
- San Diego
- University of California San Francisco
- University of Chicago
- University of Colorado
- University of Dundee
- University of Florida
- University of Georgia
- University of Glasgow
- University of Houston
- University of Manchester
- University of Maryland Baltimore
- University of Melbourne
- University of Michigan
- University of Montana
- University of Munster
- University of Oklahoma
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Pittsburgh Medical Center
- University of Sheffield
- University of Surrey
- University of Texas at El Paso
- University of Texas Health Science Center at Tyler
- University of Virginia
- University of Wisconsin
- Urovant Sciences
- US Army Medical Research and Material Command
- US Army Medical Research Institute of Chemical Defense
- Utrecht University
- UWM Research Foundation
- Vanderbilt University
- Vapotherm
- Variant Bio
- Vasomune Therapeutics
- Vectura
- Veeva Systems
- VenatoRx
- Veracyte
- Verantos
- Verily
- Verity Pharmaceuticals
- Verona Pharma
- Vicore Pharma
- Vida Diagnostics
- Virginia Catalyst
- Vituity
- Viz.ai
- Vocalis Health
- Vortran Medical
- WaVe Lifesciences
- Weill Cornell Medical College
- Windtree Therapeutics
- Wuxi STA
- Wyss Institute
- Xerox
- XL-Protein
- Xvivo Perfusion
- Xylyx Bio
- Yale School of Medicine
- Yale University
- Yissum Research Development
- ZappRx
- Zentiva
- ZEPHYRx
- Zymedi
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
